Posts

J&J pays Sail $785M, charting course to possible in vivo CAR-T buyout

on

Doctronic acquires Summer Health to expand into pediatric care

on

Argenx Acquires Forte Biosciences for $2.2 Billion to Add Phase 2‑Stage Vitiligo and Celiac Drug FB102 to Its Immunology Pipeline

on

Repligen strikes $1.5B BioLife buyout to bag cell therapy product pharmas rely on

on

Lilly bets $2.8B upfront on psychedelics in deal to buy AtaiBeckley

on

Vertex’s $10B deal for Crinetics marks its biggest acquisition to date

on

Novartis to Acquire UK Biotech Myricx Bio for Up to $1.5 Billion to Expand ADC Oncology Pipeline

on

Zymeworks agrees to acquire Theravance Biopharma for $929 million in cash plus contingent consideration

on

Biogen trims Apellis R&D after $5.6B acquisition, focuses on Empaveli and Syfovre

on

How GSK's new CEO lined up a major buyout to start his time at the top

on

Merck KGaA inks $11B Bio-Techne buyout to expand into cell therapy production

on

Merck KGaA buys Bio-Techne for $11.3 billion in largest deal in a decade

on

Friday Five: FDA steps up to counter China’s clinical‑trial edge, AbbVie buys Apogee, and psychedelics hype yields real data

on

Merck’s IBD Drug from $10.8B Prometheus Deal Claims First Phase 3 Win

on

AbbVie's $10.9B Move for Apogee's Long-Acting I&I Drug Candidates

on

Biogen acquires RayThera in up to $1B deal to bolster preclinical immunology pipeline

on

Lilly bolsters non‑opioid pain portfolio with 4E Therapeutics buy

on

GSK to Acquire Nuvalent for $10.6 Billion, Marking Its Largest Oncology Push in a Decade

on

GSK acquires lung‑cancer specialist Nuvalent for $10.6 billion

on

GSK to Acquire Nuvalent and Its Two Cancer Drugs Under FDA Review for $10.6 Billion

on